Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) saw an uptick in trading volume on Tuesday . Approximately 8,755 shares were traded during mid-day trading, an increase of 224% from the previous session’s volume of 2,699 shares.The stock last traded at $46.3750 and had previously closed at $47.30.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Zacks Research cut Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a report on Thursday, August 13th. Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Finally, Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Zealand Pharma A/S Stock Down 2.7%

The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The company has a 50-day simple moving average of $47.42 and a 200 day simple moving average of $47.50. The company has a market cap of $3.32 billion, a P/E ratio of 7.69 and a beta of 0.89.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.